GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines. 

The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and builds on Oxford’s track record in vaccine development. 

Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said: “This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.” 

Oxford has world-leading expertise in the study of precancer biology including the sequencing of neoantigens, or tumour-specific proteins that prompt the immune system to recognise cancer. This unique focus could help target the vulnerabilities of precancerous cells through an active intervention like a vaccine or targeted medicine to prevent them from progressing to cancer. 

The collaboration will add to Oxford and GSK’s existing research relationship, including the recently launched five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine. 

There are already a number of potential preventive cancer vaccines under development at Oxford. These include the LynchVax programme for people affected by Lynch syndrome (a genetic disorder that increases the risk of developing certain cancers), OvarianVax, a vaccine to teach the immune system to recognise and attack the earliest stages of ovarian cancer, and Lungvax, a vaccine designed to prevent or delay the onset of cancer in people at risk of certain types of lung cancer.

Diana Spencer, Senior Digital Content Editor, DDW